Abstract
T reatment for malignant glioma continues to evolve, and with each new advance in treatment modality there is a slight increase in overall and progression-free survival. armustine wafer treatment and systemic temozolomide plus adiotherapy have both been shown to increase patient survivorhip (8, 9). However, it is important to analyze the adverse events nd potential complications that may occur with combined treatent modalities. Initial placebo-controlled trials with carmustine afers reported numerous adverse events, the most frequent eing new onset seizures, cerebral edema, wound healing abormalities, and intracranial infection (7). Many studies are now sing carmustine wafer implantation in combination with radiaion therapy and adjuvant temozolomide chemotherapy, although vidence that this triple combination is effective is still anecdotal. n addition, the full extent of the adverse events associated with uch a combination has not been explored. In this issue, Della uppa et al. (2) in their article, “Carmustine Wafers Implantation hen Surgical Cavity Is Communicating With Cerebral Ventriles: Technical Considerations on a Clinical Series,” explore one f the lesser mentioned adverse events associated with carmusine wafers, hydrocephalus.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call